Related Experiment Video

Updated: Aug 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Novel perspective approaches to the therapy of dyslipidaemias]

A Adameová1, M Kuzelová, P Svec

  • 1Farmaceutická fakulta Univerzity Komenského v Bratislave, Katedra farmakológie a toxikológie. adameova@fpharm.uniba.sk

Ceska a Slovenska Farmacie : Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti
|June 11, 2005
PubMed

Insights

New hypolipidemic drugs offer alternatives for managing high cholesterol and cardiovascular disease risk. These novel agents target cholesterol pathways, addressing limitations of current statin therapies.

Area of Science:

  • Pharmacology and Biochemistry
  • Cardiovascular Medicine

Context:

  • Elevated lipid concentrations are a primary risk factor for cardiovascular diseases (CVDs).
  • Statins are effective lipid-modifying therapies but have limitations like intolerance and adverse events.
  • There is a need for alternative hypolipidemic agents to manage cholesterol levels and reduce CVD morbidity and mortality.

Purpose:

  • To review novel hypolipidemic drugs targeting cholesterol metabolism.
  • To discuss the physiological and pharmacological mechanisms of these new agents.
  • To explore their potential in managing dyslipidemia and preventing atherosclerosis.

Summary:

  • This paper examines emerging hypolipidemic drugs that modulate cholesterol's fate.
  • Investigated agents include cholesterol absorption inhibitors, ACAT inhibitors, MTP inhibitors, farnesoid X receptor antagonists, and SREBP-SCAP ligands.
  • These novel substances offer potential hypolipidemic and anti-atherosclerotic benefits.

Impact:

  • Provides insights into next-generation therapies for dyslipidemia.
  • Highlights agents that may overcome statin intolerance or achieve target lipid levels.
  • Contributes to the development of improved strategies for cardiovascular disease prevention.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications